
    
      This is a multicenter, prospective, randomized, open-label phase IV study.

      Compare ledipasvir/sofosbuvir + ribavirin for 12 weeks vs ledipasvir/sofosbuvir alone for 12
      weeks in patients over 90 days post-liver transplant
    
  